- Net loss: $45.6M or ($0.41)/share vs $27.4M or ($0.26)/share in Q1 2024
- R&D expense: $41.4M, +72% YoY
- Cash & equivalents: $852M vs $903M as of Dec 31, 2024
CEO Brian Lian: "We continued to ramp up activities in support of the initiation of Phase 3 trials with the subcutaneous formulation of VK2735... and completed enrollment in our Phase 2 oral dosing trial."
🌱Revenue & Growth
- Revenue: $0 (no revenue reported, clinical-stage company)
- No commercial products; pipeline in clinical development stages
💰Profits & Health
- Net loss: $45.6M vs $27.4M in Q1 2024
- R&D: $41.4M vs $24.1M in Q1 2024
- G&A: $14.1M vs $10.0M in Q1 2024
- Interest income: $9.9M vs $6.7M in Q1 2024
- Cash, cash equivalents & short-term investments: $852M
- Shares outstanding: 112.1M
📌Business Highlights
- Phase 2 VENTURE-Oral trial (13-week dosing) fully enrolled (~280 subjects)
- Phase 3 trials for SC VK2735 in obesity to begin Q2 2025
- DACRA program advancing; IND filing expected 2H25
- Manufacturing agreement signed with CordenPharma for VK2735 API + fill/finish
- Strong cash runway supports pipeline development
🔮Future Outlook
- VENTURE-Oral data readout expected in 2H25
- Phase 3 VK2735 SC trials to start Q2 2025
- IND submission for DACRA program in 2H25
- Continued R&D investment to support VK2735, VK2809, VK0214 development